Author: Chen, Zhitao ; Yuan, Feng ; Wu, Xiang’an ; Lan, Lan ; Dai, Tianxing ; He, Jianxing ; Li, Kai ; Xie, Shulan ; Gui, Dan ; Wang, Guoying ; Chen, Jianfeng ; Yang, Hanyu ; Yang, Jianliang

BACKGROUND:

Whether a laryngeal mask airway (LMA) can be safely used during liver transplantation remains unclear. However, in clinical practice, the choice of an airway device may also reflect a broader recovery-oriented perioperative strategy rather than an isolated technical substitution.

METHODS:

We retrospectively reviewed adult patients who underwent primary elective liver transplantation at our center between January 2024 and November 2025. The patients were grouped according to their primary intraoperative airway device (LMA or endotracheal tube [ETT]). Propensity score matching was used to reduce baseline imbalance. Intraoperative variables, postoperative airway-related events, postoperative pulmonary complications (PPCs), intensive care unit (ICU) stays, and postoperative hospital stays were compared.

RESULTS:

After matching, 25 and 44 patients in the LMA and ETT groups, respectively, were analyzed. The LMA group showed a higher rate of immediate airway device removal, lower rocuronium use during anesthetic maintenance, less postoperative noninvasive ventilation, less postoperative sore throat, and a shorter postoperative hospital stay. PPCs were numerically less frequent in the LMA group, but the between-group difference was not statistically significant after matching. No increase in major airway-related adverse events was observed in the LMA group.

CONCLUSIONS:

In carefully selected liver transplant recipients, use of LMA within a recovery-oriented perioperative context appeared feasible and was associated with several favorable early postoperative outcomes.

01 Dec 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Rapid screening of physicochemical compatibility between co-administered injectable drugs using thermal and spectroscopic approaches

Article

Author: Medeiros-Souza, Patrícia ; Gratieri, Tais ; Lima, Ana Luiza ; Granados, Pedro A ; Santana, Ingrid A ; Cunha-Filho, Marcilio ; Gross, Idejan P ; Gelfuso, Guilherme M ; Sa-Barreto, Livia

The concomitant administration of injectable drugs in hospital settings frequently involves extemporaneous combinations within the same infusion line, often without compatibility evaluation. This practice may compromise drug stability and patient safety, particularly in intensive care units characterized by complex polypharmacy regimens. In this study, a rapid screening protocol based on complementary thermal, spectroscopic, and morphological techniques was applied to investigate potential physicochemical interactions between injectable drugs under accelerated stress conditions. Dopamine, ondansetron, rocuronium, and fluconazole were combined pairwise as binary physical mixtures and subjected to controlled thermal and photonic stress. Differential scanning calorimetry, thermogravimetric analysis, FTIR spectroscopy, and stereomicroscopy were employed to detect early physicochemical interactions and stress-induced instability. Thermal analysis revealed melting point shifts, enthalpy reduction, amorphization, and premature degradation events for several combinations, indicating different levels of intermolecular interaction. FTIR and morphological analyses demonstrated that some changes in thermal profile were accompanied by chemically relevant alterations and progressive discoloration, particularly after combined thermal and light exposure. Dopamine/fluconazole and dopamine/ondansetron mixtures showed evidence of moderate solid-state interaction, while ondansetron/fluconazole exhibited increased susceptibility to stress-induced instability. Mixtures containing rocuronium exhibited greater sensitivity to combined thermal and photonic stress, especially ondansetron/rocuronium, which showed marked light-dependent instability. Overall, the proposed approach proved useful as a rapid preliminary risk-ranking strategy to identify injectable drug combinations requiring further compatibility investigation under clinically relevant conditions.

01 Nov 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

A multi-center retrospective cohort study of SUGAmmadex for neuromuscular blockade reversal in the emergency department: SUGARED study - on behalf of EMPHARM-NET Investigators

Article

Author: Rech, Megan A ; Van Wert, Elizabeth ; Fletcher, Ana Avram ; Mattson, Alicia E ; Brown, Caitlin S ; Celmins, Laura ; Howington, Gavin T ; Sun, Jiayi ; Sindelar, Morganne ; Woolum, Jordan A ; Coralic, Zlatan ; Zepeski, Anne ; Faine, Brett ; Zimmerman, David E ; Krenz, James ; Lawson, Christine

STUDY OBJECTIVE:

The objective of this study was to describe the proportion of emergency department (ED) patients with traumatic brain injury (TBI) or spontaneous intracranial hemorrhage (sICH) who demonstrated a positive neurologic response to sugammadex-mediated reversal of rocuronium, and to compare outcomes between responders and non-responders.

METHODS:

This was a multicenter, retrospective, observational cohort study of 11 US Emergency Departments. Adult patients, aged ≥18 years, who were intubated using rocuronium and subsequently received sugammadex and had a primary diagnosis of TBI or sICH between December 15, 2015, to June 30, 2024 were screened for inclusion. The primary outcome of this study was the proportion of patients who had a positive response (defined as an increase in GCS of ≥1 point) within 30 min of sugammadex administration. The secondary outcomes included change in analgosedation requirements during the first 30 min post-sugammadex administration, and the rate of neurosurgical procedures.

RESULTS:

The primary outcome analysis included 362 patients. An increase in GCS within 30 min post-sugammadex administration occurred in 54% (n = 196), with a median GCS change of 3 (IQR: 2-4, range 1-9). A positive response was associated with the addition of a new analgesic agent (30.6% 13.9%, difference = 16.8%, 95% confidence interval 8.4 to 25.1), sedation agent (33.7% vs. 14.5%, difference = 19.2%, 95% confidence interval 10.7 to 27.7), and a non-significant increase in neurosurgical procedures (43.4 vs. 33.7%, difference = 9.6%, 95% confidence interval -0.4 to 19.7).

CONCLUSION:

Sugammadex administration to reverse rocuronium in the ED was associated with a significant change in GCS and analgosedation requirements.

News (Medical) associated with Rocuronium Bromide

03 Sep 2026

·www.biospace.com

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

Product Launch Fresenius Kabi announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Offering Sugammadex in a prefilled syringe further expands the use of the Simplist ® portfolio into operating rooms. Simplist ® single-dose, prefilled syringes require no assembly at the point of care, help streamline medication management, and eliminate steps where errors can occur. LAKE ZURICH, Ill.--(BUSINESS WIRE)-- #FreseniusCommittedToLife --Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion ® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist ® ready-to-administer prefilled syringe. Simplist ® single-dose, prefilled syringes require no assembly at the point of care, help streamline medication management, and eliminate steps where errors can occur. Sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Fresenius Kabi offers Sugammadex in the following product presentation: 200 mg per 2 mL Simplist ® prefilled syringe “The opening of the Sugammadex market in the United States marks an important milestone for anesthesia teams and for patient access,” said Joel Rosenstack, President, Pharmaceuticals, Fresenius Kabi USA. “As clinical demand for Sugammadex continues to grow, Fresenius Kabi’s ready‑to‑administer prefilled syringe gives clinicians an option for more efficient medication management in the operating room with less risk for error.” More in America Fresenius Kabi’s Sugammadex products are filled, formulated, and packaged in the United States, reflecting the company’s More in America commitment to strengthening domestic pharmaceutical manufacturing and enhancing supply‑chain resiliency. ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); “Our U.S. production capabilities are central to ensuring reliable access to essential medicines,” said Lindsey Thomas, Senior Vice President, Pharmaceutical Marketing. “Formulating, filling, and packaging Sugammadex in America underscores our long‑standing investment in strengthening the U.S. supply chain and supporting the surgical teams who depend on these medicines every day.” As part of the Fresenius Group and its #FutureFresenius strategy, Fresenius Kabi is committed to strengthening healthcare resilience through reliable access to high-quality essential medicines. The launch of Sugammadex further enhances the company’s U.S. pharmaceutical portfolio and supports healthcare providers in delivering safe and effective patient care. Availability Fresenius Kabi Sugammadex Injection products are available for ordering beginning today through Fresenius Kabi sales representatives or Customer Service at (888) 386-1300. For full prescribing information, please consult the product labeling. ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Sugammadex Injection is contraindicated in patients with a known hypersensitivity to Sugammadex or any of its components. WARNINGS AND PRECAUTIONS Anaphylaxis: Be prepared for hypersensitivity reactions (including anaphylactic reactions) and take necessary precautions. Marked Bradycardia: Cases of marked bradycardia, some of which have resulted in cardiac arrest, have been observed within minutes after administration. Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. Respiratory Function Monitoring: Ventilatory support is mandatory until adequate spontaneous respiration is restored and the ability to maintain a patent airway is assured. Provide adequate ventilation if neuromuscular blockade persists after Sugammadex Injection or recurs following extubation. Waiting Times for Re-Administration of Neuromuscular Blocking Agents: If re-administration of neuromuscular blocking agent is required after reversal with Sugammadex Injection, waiting times should be based on the dose of Sugammadex Injection, and the renal function of the patient. Consider use of a nonsteroidal neuromuscular blocking agent. ADVERSE REACTIONS ezstandalone.cmd.push(function () { ezstandalone.showAds(134); }); Most common adverse reactions (reported in ≥10% of adult patients at a 2, 4, or 16 mg/kg Sugammadex Injection dose and higher than the placebo rate): vomiting, pain, nausea, hypotension, and headache. Most common adverse reactions (reported in ≥10% of pediatric patients 2 to <17 years of age at Sugammadex Injection doses of 2 or 4 mg/kg) were pain, vomiting, and nausea. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or . DRUG INTERACTIONS Toremifene: Concomitant use can delay recovery. Hormonal contraceptives: Patients must use an additional, non-hormonal method of contraception for 7 days following Sugammadex Injection administration. USE IN SPECIFIC POPULATIONS Not recommended in patients with severe renal impairment. INDICATIONS AND USE ezstandalone.cmd.push(function () { ezstandalone.showAds(135); }); Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. Additional pediatric use information is approved for Merck Sharp & Dohme LLC’s BRIDION ® (sugammadex) injection. However, due to Merck Sharp & Dohme LLC’s marketing exclusivity rights, this drug product is not labeled with that information. This Important Safety Information does not include all the information needed to use Sugammadex Injection safely and effectively. Please see full prescribing information for Sugammadex Injection at . About Fresenius Kabi Fresenius Kabi is part of the global healthcare company Fresenius and specializes in lifesaving medicines, medical technologies, and services for critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi’s broad portfolio enables access to high-quality products across emergency medicine, surgery, oncology, intensive care, and at home – reaching around 450 million patients each year. Through complementary business areas, Fresenius Kabi offers highly complex biopharmaceuticals for the treatment of cancer, autoimmune and endocrine diseases; leading enteral, parenteral and homecare solutions within medical nutrition; innovative medical technology including infusion pumps, cell and gene therapy devices, disposables and blood collection systems; and intravenous generic drugs and fluids that are vital to the work of healthcare providers globally. For more information, please visit . About Fresenius Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025. For more information, visit and follow Fresenius on LinkedIn . Contacts For more information, please contact: Matthew Kuhn, tel:1-847-220-3033; Matt.Kuhn@fresenius-kabi.com

04 Aug 2026

·www.biospace.com

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- $RDY #Bridion --Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion®, in the United States (US), expanding its hospital portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy's global supply network. Dr. Reddy's launch of the product is on the first day of generic availability in the United States, underscoring the Company's commitment to execution excellence and supply reliability. Sugammadex Injection (100mg/ml) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. The Bridion® brand (100mg/ml) had U.S. sales of approximately $1.6 billion for the latest 12-month period ended May 2026, according to IQVIA National Sales Perspectives data. Bridion® is a registered trademark of Merck Sharp & Dohme B.V. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); About Dr. Reddy’s : Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: . Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein. Contacts INVESTOR RELATIONS AISHWARYA SITHARAM AISHWARYASITHARAM@DRREDDYS.COM MEDIA RELATIONS SANTOSH VYAS SANTOSHVYAS@DRREDDYS.COM

Drug Approval

30 Jul 2026

·www.prnewswire.com

Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection

MUMBAI, India and NAPLES, Fla., July 30, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States. Lupin's Sugammadex Injection is the bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery. About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 26,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn Safe Harbor Statement Bridion is a registered trademark of Merck Sharp & Dohme B.V. SOURCE Lupin Pharmaceuticals, Inc. 21% more press release views with Request a Demo

Drug Approval

100 Deals associated with Rocuronium Bromide

External Link

KEGG	Wiki	ATC	Drug Bank
D00765	Rocuronium Bromide	M03AC09	DBSALT000575

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	China	Organon NV	07 Oct 2000
Anesthesia	United States	Organon USA, Inc.	17 Mar 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Voice Disorders	Phase 1	Canada	Merck Sharp & Dohme Corp.	01 Jul 2017
Ventilator-Induced Lung Injury	Clinical	United States	Merck Sharp & Dohme Corp.	01 Jan 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05887375 (CTgov)	Phase 4	Reversal of Neuromuscular Blockade \| Urinary Retention	118	sugammadex+Rocuronium (Sugammadex 2 mg/kg)	suaedithde = xpqrdidcun gmrwyuegfy (gioyeksxnn, guajhkjfdg - pyzildeuzx) View more	-	07 Oct 2026
				Glycopyrrolate+Neostigmine+Rocuronium (Neostigmine + Glycopyrrolate)	suaedithde = rranyyzipa gmrwyuegfy (gioyeksxnn, iozmcsphzm - jvpibzukww) View more
NCT07092046 (CTgov)	Not Applicable	Anesthesia \| Infectious Diseases	140	Microbiological Culture and Identification+Fentanyl+Sugammadex 200 MG in 2 ML Injection+Propofol 1%+Atropine Sulphate+Lidocaine+Rocuronium 50 mg/5 ml+Ephedrine Hydrochloride+Remifentanil 2 MG (Minimal Flow Anesthesia (0.5 L/Min))	upjfyjizna = vkdeqkycjb dvcyeqedil (qcpofhgyyq, pwpepneylk - gagmofgghx) View more	-	05 Oct 2026
				Microbiological Culture and Identification+Fentanyl+Sugammadex 200 MG in 2 ML Injection+Propofol 1%+Atropine Sulphate+Lidocaine+Rocuronium 50 mg/5 ml+Ephedrine Hydrochloride+Remifentanil 2 MG (Standard Flow Anesthesia (2 L/Min))	upjfyjizna = hxyrucadqj dvcyeqedil (qcpofhgyyq, zdzvkxtjfe - hbwwrrlozt) View more
NCT02400931 (Pubmed \| BMC Anesthesiol)	Not Applicable	-	288	rocuronium 0.6 mg/kg (Tracheal intubation with face-mask ventilation (FMV))	mpnolpoxfp(yvdcxjfvsv) = kszyictvno msppmplell (kouksmpxvk ) View more	Negative	19 Sep 2026
				rocuronium 1.2 mg/kg (Tracheal intubation without face-mask ventilation (FMV))	mpnolpoxfp(yvdcxjfvsv) = fspaqfkpun msppmplell (kouksmpxvk )
NCT06564857 (ROCVIDEO, Pubmed \| Acta Anaesthesiol Scand)	Phase 4	Anesthesia	2,684	Rocuronium	yvcwvncckf(cumxekacam) = vscognouzv ccalyivaxx (upzktufifo )	Positive	01 Jul 2026
				Remifentanil	yvcwvncckf(cumxekacam) = eikfnldfgd ccalyivaxx (upzktufifo )
NCT05562999 (Pubmed \| Anesth Analg)	Phase 4	Reversal of Neuromuscular Blockade	100	Rocuronium (Deep Neuromuscular Blockade)	hmiwholzor(omuuwhtmjv) = gkhvadkdyn onkgqwonjx (kidzhsyham, 826 - 1940) View more	Negative	01 Feb 2026
				Rocuronium (Moderate Neuromuscular Blockade)	hmiwholzor(omuuwhtmjv) = pztllbpxdn onkgqwonjx (kidzhsyham, 545 - 1970) View more
NCT05279898 (PATHFINDERII, CTgov)	Not Applicable	Cognitive Dysfunction \| Pain \| Emergence Delirium	70	dexmedetomidine+EEG Monitoring+Ropivacaine+Propofol+Rocuronium+Ketamine+Remifentanil (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided)	wmosjtgnvq(nxqrzpvonk) = fwrsvilnxz yajdrfxkga (tzxetjsedv, 28.5) View more	-	26 Nov 2025
				Dexmedetomidine+fentanyl+Hydromorphone+Acetaminophen+Oxycodone+Propofol+Sevoflurane+Lidocaine (Standard of Care/Control)	wmosjtgnvq(nxqrzpvonk) = zfwrgvzxaa yajdrfxkga (tzxetjsedv, 79.9) View more
NCT03434678 (CTgov)	Phase 3	Pancreatic Cancer	133	Open Pancreaticoduodenectomy+Propofol+Fentanyl Inhalational Agent+Rocuronium+Bupivacaine (Epidural-General Anesthesia)	zwgyudapjz = hjxtxhlvju tgsjuvmeno (htwdsjnims, yejdzbjdyt - dlljmlgyyh) View more	-	30 Jul 2025
				Open Pancreaticoduodenectomy+Propofol+Fentanyl+Rocuronium (General Anesthesia)	zwgyudapjz = esiyoyjpke tgsjuvmeno (htwdsjnims, ueqvzbhera - vrgzummuzj) View more
NCT06225466 (CTgov)	Phase 4	-	172	sugammadex+Rocuronium (Neuromuscular Blockade)	usxajssduk(seetrgwpyx) = cgkfdulcpo fmkrazqggv (etzuhcddry, 0.009) View more	-	28 Jul 2025
				Anesthesia without neuromuscular blockade (No Neuromuscular Blockade)	usxajssduk(seetrgwpyx) = oyqiuxwlqz fmkrazqggv (etzuhcddry, 0.009) View more
NCT03808077 (CTgov)	Phase 2	Prostatic Cancer \| Pain, Postoperative	139	Rocuronium (Interventional Group: Deep Neuromuscular Blockade)	nozbcudwkc(yxyrmuetqe) = leglrcwwoz afuqcqdowc (utvlxwvqui, gbkwnnyddl - mxgjehhncf) View more	-	19 Jun 2025
				Rocuronium (Control Group: Moderate Neuromuscular Blockade)	nozbcudwkc(yxyrmuetqe) = aotlwramds afuqcqdowc (utvlxwvqui, erupzbjzmh - iyrzowekfm) View more
AAAAI2025	Not Applicable	Anaphylaxis	73	Cefazolin	nkrasezkdh(edffzlgfvs) = ompjoezakc aduspueigp (zqiwzbzmgj ) View more	Positive	28 Feb 2025
				Chlorhexidine	pkmwfgtons(fibjigeuim) = ijstjesmcp bjzptuevlg (ezzulqejqw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis